Literature DB >> 19460786

Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study.

W M Vollmer1, Thorn Gíslason, P Burney, P L Enright, A Gulsvik, A Kocabas, A S Buist.   

Abstract

Published guidelines recommend spirometry to accurately diagnose chronic obstructive pulmonary disease (COPD). However, even spirometry-based COPD prevalence estimates can vary widely. We compared properties of several spirometry-based COPD definitions using data from the international Burden of Obstructive Lung Disease (BOLD)study. 14 sites recruited population-based samples of adults aged > or =40 yrs. Procedures included standardised questionnaires and post-bronchodilator spirometry. 10,001 individuals provided usable data. Use of the lower limit of normal (LLN) forced expiratory volume in 1 s (FEV(1)) to forced vital capacity (FVC) ratio reduced the age-related increases in COPD prevalence that are seen among healthy never-smokers when using the fixed ratio criterion (FEV(1)/FVC <0.7) recommended by the Global Initiative for Chronic Obstructive Lung Disease. The added requirement of an FEV(1) either <80% predicted or below the LLN further reduced age-related increases and also led to the least site-to-site variability in prevalence estimates after adjusting for potential confounders. Use of the FEV(1)/FEV(6) ratio in place of the FEV(1)/FVC yielded similar prevalence estimates. Use of the FEV(1)/FVC<LLN criterion instead of the FEV(1)/FVC <0.7 should minimise known age biases and better reflect clinically significant irreversible airflow limitation. Our study also supports the use of the FEV(1)/FEV(6) as a practical substitute for the FEV(1)/FVC.

Entities:  

Mesh:

Year:  2009        PMID: 19460786      PMCID: PMC3334278          DOI: 10.1183/09031936.00164608

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction.

Authors:  M P Swanney; R L Jensen; D A Crichton; L E Beckert; L A Cardno; R O Crapo
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

2.  The FEV1/FEV6 predicts lung function decline in adult smokers.

Authors:  R L Enright; J E Connett; W C Bailey
Journal:  Respir Med       Date:  2002-06       Impact factor: 3.415

3.  Efficacy of the FEV1/FEV6 ratio compared to the FEV1/FVC ratio for the diagnosis of airway obstruction in subjects aged 40 years or over.

Authors:  F W Rosa; R Perez-Padilla; A Camelier; O A Nascimento; A M B Menezes; J R Jardim
Journal:  Braz J Med Biol Res       Date:  2007-10-29       Impact factor: 2.590

4.  Definition of COPD: based on evidence or opinion?

Authors:  R Pellegrino; V Brusasco; G Viegi; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N Macintyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2008-03       Impact factor: 16.671

5.  Reference ranges for spirometry across all ages: a new approach.

Authors:  Sanja Stanojevic; Angie Wade; Janet Stocks; John Hankinson; Allan L Coates; Huiqi Pan; Mark Rosenthal; Mary Corey; Patrick Lebecque; Tim J Cole
Journal:  Am J Respir Crit Care Med       Date:  2007-11-15       Impact factor: 21.405

6.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Authors:  P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

7.  Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition.

Authors:  G Viegi; M Pedreschi; F Pistelli; F Di Pede; S Baldacci; L Carrozzi; C Giuntini
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

8.  Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction.

Authors:  M P Swanney; G Ruppel; P L Enright; O F Pedersen; R O Crapo; M R Miller; R L Jensen; E Falaschetti; J P Schouten; J L Hankinson; J Stocks; P H Quanjer
Journal:  Thorax       Date:  2008-09-11       Impact factor: 9.139

9.  Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers.

Authors:  J A Hardie; A S Buist; W M Vollmer; I Ellingsen; P S Bakke; O Mørkve
Journal:  Eur Respir J       Date:  2002-11       Impact factor: 16.671

10.  Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes.

Authors:  I Cerveri; A G Corsico; S Accordini; R Niniano; E Ansaldo; J M Antó; N Künzli; C Janson; J Sunyer; D Jarvis; C Svanes; T Gislason; J Heinrich; J P Schouten; M Wjst; P Burney; R de Marco
Journal:  Thorax       Date:  2008-05-20       Impact factor: 9.139

View more
  68 in total

Review 1.  Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: new insights.

Authors:  Jacob Gelberg; R Andrew McIvor
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  [Pulmonary diseases in the elderly].

Authors:  M Gogol; H J Heppner
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

Review 3.  Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  M Bradley Drummond; A Sonia Buist; James D Crapo; Robert A Wise; Stephen I Rennard
Journal:  Ann Am Thorac Soc       Date:  2014-04

4.  Does Low FEV1 in Addition to Fixed Ratio and/or Lower Limit of Normal of FEV1/FVC Improve Prediction of Mortality in COPD? The NHANES-III-linked-mortality Cohort.

Authors:  Yewande E Odeyemi; O'Dene Lewis; Julius Ngwa; Kristen Dodd; Richard F Gillum; Alem Mehari
Journal:  J Natl Med Assoc       Date:  2018-07-29       Impact factor: 1.798

5.  Exposure to PM10 as a risk factor for the development of nasal obstruction and chronic obstructive pulmonary disease.

Authors:  Lazaros Sichletidis; Dionisios Spyratos; Anastasios Tsiotsios; Anna-Bettina Haidich; Ioannis Ganidis; Dimitrios Michailidis; Georgios Triantafyllou; George Kottakis; Dimitrios Melas
Journal:  Int J Occup Environ Health       Date:  2014 Jan-Mar

6.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

7.  Genetic ancestry and the relationship of cigarette smoking to lung function and per cent emphysema in four race/ethnic groups: a cross-sectional study.

Authors:  Rhea Powell; Duncan Davidson; Jasmin Divers; Ani Manichaikul; J Jeffrey Carr; Robert Detrano; Eric A Hoffman; Rui Jiang; Richard A Kronmal; Kiang Liu; Naresh M Punjabi; Eyal Shahar; Karol E Watson; Jerome I Rotter; Kent D Taylor; Stephen S Rich; R Graham Barr
Journal:  Thorax       Date:  2013-04-12       Impact factor: 9.139

8.  Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction.

Authors:  Surya P Bhatt; Jessica C Sieren; Mark T Dransfield; George R Washko; John D Newell; Douglas S Stinson; Gideon K D Zamba; Eric A Hoffman
Journal:  Thorax       Date:  2013-03-23       Impact factor: 9.139

9.  A Novel Spirometric Measure Identifies Mild COPD Unidentified by Standard Criteria.

Authors:  Asli Gorek Dilektasli; Janos Porszasz; Richard Casaburi; William W Stringer; Surya P Bhatt; Youngju Pak; Harry B Rossiter; George Washko; Peter J Castaldi; Raul San Jose Estepar; James E Hansen
Journal:  Chest       Date:  2016-07-22       Impact factor: 9.410

10.  Case-finding options for COPD: results from the Burden of Obstructive Lung Disease study.

Authors:  Anamika Jithoo; Paul L Enright; Peter Burney; A Sonia Buist; Eric D Bateman; Wan C Tan; Michael Studnicka; Filip Mejza; Suzanne Gillespie; William M Vollmer
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.